New perspectives in occult hepatitis C virus infection

Vicente Carreño, Javier Bartolomé, Inmaculada Castillo, Juan Antonio Quiroga

Abstract
Occult hepatitis C virus (HCV) infection, defined as the presence of HCV RNA in liver and in peripheral blood mononuclear cells (PBMCs) in the absence of detectable viral RNA in serum by standard assays, can be found in anti-HCV positive patients with normal serum levels of liver enzymes and in anti-HCV negative patients with persistently elevated liver enzymes of unknown etiology. Occult HCV infection is distributed worldwide and all HCV genotypes seem to be involved in this infection. Occult hepatitis C has been found not only in anti-HCV positive subjects with normal serum levels of liver enzymes and in anti-HCV negative patients with persistently elevated liver enzymes of unknown etiology. Occult HCV infection is distributed worldwide and all HCV genotypes seem to be involved in this infection. Occult hepatitis C has been found not only in anti-HCV positive subjects with normal serum levels of liver enzymes and in chronic hepatitis of unknown origin but also in several groups at risk for HCV infection such as hemodialysis patients or family members of patients with occult HCV. This occult infection has been reported also in healthy populations without evidence of liver disease. Occult HCV infection is less aggressive than chronic hepatitis C although patients affected by occult HCV may develop liver cirrhosis and even hepatocellular carcinoma. Thus, anti-HCV negative patients with occult HCV may benefit from antiviral therapy with pegylated-interferon plus ribavirin. The persistence of very low levels of HCV RNA in serum and in PBMCs, along with the maintenance of specific T-cell responses against HCV-antigens observed during a long-term follow-up of patients with occult hepatitis C, indicate that occult HCV is not a persistent infection that is not spontaneously eradicated. This is an updated report on diagnosis, epidemiology and clinical implications of occult HCV with special emphasis on anti-HCV negative cases.

Key words: Occult hepatitis C virus; Hepatitis C virus RNA; Liver; Peripheral blood mononuclear cells; T-cell response

INTRODUCTION
The hepatitis C virus (HCV), an enveloped single-stranded RNA virus, was identified in 1989 and was classified within the Flaviviridae family as a separate genus (Hepacivirus)\(^1\). The virus replicates by the synthesis of the complementary RNA strand (the so-called negative or antigenomic strand)\(^2\). So far, six major genotypes (HCV-1 to HCV-6) have been described, each containing multiple subtypes\(^3\), with significant differences in their global distribution and prevalence\(^4\). It is estimated that about 170 million people, 3% of the world’s population, are infected with HCV\(^5\) and it is a leading cause of chronic liver disease worldwide including cirrhosis and hepatocellular carcinoma\(^6\). The diagnosis of HCV infection is made by the detection of antibodies against HCV (anti-HCV) and/or by detecting the presence of the HCV RNA in serum\(^7\).
However, a new entity of HCV infection was first described in 2004 in patients with persistently elevated liver function tests and who were anti-HCV and serum HCV RNA negative\(^8\). Despite the absence of conventional HCV markers, 57% of these patients had HCV RNA in the liver and so this clinical situation was termed "occult HCV infection". Moreover, it was proven that the antigenic HCV RNA strand could be detected also in the hepatocytes of a high proportion of those patients with occult HCV infection, this indicating an active viral replication. Occult HCV infection has also been described in two other different clinical settings. One of these is in anti-HCV positive, serum HCV-RNA negative subjects with persistent normal values of liver enzymes (asymptomatic HCV carriers), of whom nearly 90% have detectable viral RNA in liver and in peripheral blood mononuclear cells (PBMCs)\(^9\). The second one is in anti-HCV positive individuals who resolved HCV infection either spontaneously or after antiviral treatment\(^10\). In these patients, HCV RNA is detected in liver and in PBMCs years after apparent recovery from the disease (normalization of liver enzyme values and loss of serum HCV RNA). This occult HCV infection is related to the persistence of necroinflammation activity in the liver of the sustained responders. Thus, there are two types of occult HCV infection: one can be found among anti-HCV seropositive individuals with normal values of liver enzymes and the other is found among anti-HCV seronegative patients with abnormal levels of liver enzymes.

The present review focuses on the latest studies of occult HCV infection performed in anti-HCV negative and serum HCV RNA negative patients.

### IDENTIFICATION OF OCCULT HCV INFECTION

Occult HCV infection was first identified in liver of anti-HCV and serum HCV RNA negative patients with abnormal liver function tests and it was also found that viral RNA could be present in the PBMCs of nearly 70% of these patients\(^9\). Furthermore, it was demonstrated that occult HCV replicates in these cells\(^11\). By detecting HCV RNA in liver biopsies or in PBMCs, other groups in Japan, Italy, Egypt, Colombia, Pakistan and Iran\(^12\) have confirmed the existence of occult HCV infection in patients with elevated liver enzymes and without conventional HCV markers (Table 1). Occult HCV infection has also been found in hemodialysis patients who were persistently anti-HCV and serum HCV RNA negative but with abnormal values of liver enzymes\(^13\) in the family setting of patients with occult hepatitis C\(^13\) and even in healthy subjects with normal alanine aminotransferase (ALT) levels and no clinical evidence of liver disease\(^13\).

Since HCV was replicating in the liver and PBMCs of patients with occult HCV infection, it was speculated that it should exist as circulating viral particles but at such low levels that the virions could not be detected even using the most sensitive reverse-transcription polymerase chain reaction (RT-PCR) techniques. This hypothesis was tested by concentrating HCV virions by ultracentrifugation of 2 mL of serum from patients with occult HCV prior to HCV RNA detection by RT-PCR\(^17\). In this way, serum viral RNA was found in nearly 60% of the patients. In addition, it was found that the density of the viral particles isolated from patients with occult HCV infection was similar to the highly-infectious lipoviral particles present in the serum of patients with classical chronic hepatitis C\(^17\), suggesting that serum from patients with occult HCV is potentially infectious.

### HCV-SPECIFIC T-CELL RESPONSES AND THE OCCULT INFECTION

Functional virus-specific memory CD4\(^+\) and CD8\(^+\) T-cells have been documented in the circulation of patients with HCV RNA persistence in the liver and so assaying cellular immunity has been proposed as a surrogate marker of occult HCV infection\(^9,30\). To test HCV-specific T-cell responses, PBMCs isolated from fresh heparinized venous blood by gradient centrifugation are washed twice in phosphate-buffered saline and resuspended in RPMI-1640 medium, supplemented with 10% heat-inactivated fetal bovine serum, 2 mmol/L glutamine and antibiotics. PBMCs are cultured in triplicate (1.0 × 10\(^5\) viable cells/100 μL) in flat-bottomed 96-well culture plates at 37 °C, 5% CO\(_2\) and humidity in the presence or absence of 1 μg/mL HCV proteins core, NS3 and NS4; Staphylococcus aureus enterotoxin B (10 μg/mL) is used as positive control. On day 6, cultures are pulsed with 1 μCi/well of 3H-thymidine for 16 h and then harvested and transferred to filters and the incorporated radioactivity measured\(^30\).

T-cell responses found in occult HCV infection are similar to those described in anti-HCV-positive patients following spontaneous or treatment-induced recovery\(^32,33\). HCV-specific T-cell responses have been detected often among occult HCV-infected hemodialysis patients\(^35\), family members of patients with occult or overt HCV infection\(^36\) and among HCV-seronegative sexual partners of patients with chronic hepatitis C (Aguilar-Reina J, personal communication), supporting exposure to trace amounts of HCV RNA. The maintenance of such immune responses may require only a low level of productive infection. In fact, sporadic reappearance of minute amounts of HCV RNA stimulates cellular immunity\(^37\). However, persistence of occult HCV in face of adaptive cellular responses indicates that the latter do not ultimately result in sterilising immunity. The actual impact on the natural history of the occult infection is still a matter of debate. Indeed, HCV-specific T-cell responses have been described in apparently healthy persons, as well as in those who likely have resolved the infection or who have been exposed to, but who apparently did not become infected by, HCV\(^38\). To summarize, T-cell responses are more frequent and stronger compared with chronic hepatitis C patients\(^39\), contributing to control the
Asymptomatic anti-HCV carrier

57/100 (57%)

Cohort/setting

Not reported

Cryptogenic cirrhosis with HCC

11/11 (100%)

Cryptogenic chronic hepatitis

Therapy response

Not applicable

Country

1b, 2, 3

1a, 1b, 3a

1a, 1b, 2a

General population without liver disease

June 21, 2012

15/17 (88%)

4/40 (10%)

17/18 (94%)

Not reported

Asymptomatic anti-HCV carrier and therapy response

9/276 (3.3%)

Liver retransplantation

Not applicable

Ref.

7/62 (11%)

Not reported

Spontaneous recovery and therapy response

1a

Therapy response

1a, 1b, 3a

Therapy response

1a, 1b, 3a

Therapy response

1a, 1b, 2a

Therapy response

Not reported

Anti-HCV positive

United States/Poland

11/11 (100%)

1a, 1b

Asymptomatic anti-HCV carrier

Spain

17/18 (94%)

Not reported

Asymptomatic HCV carrier and therapy response

Spain

10/12 (83%)

1b

Asymptomatic anti-HCV carrier

Canada

16/16 (100%)

1a, 1b, 2a

Spontaneous recovery and therapy response

United States/Poland

15/17 (88%)

1a, 1b, 2a

Therapy response

Spain

19/20 (95%)

1b, 2, 3

Therapy response

Canada

24/24 (100%)

1a, 1b, 3a

Therapy response

Egypt

7/62 (11%)

Not reported

Therapy response


Hepatitis C virus (HCV) RNA detection in liver and/or peripheral blood mononuclear cells; *including HCV RNA detection in serum with nested reverse-transcription polymerase chain reaction-nucleic acid hybridization assay. HCC: Hepatocellular carcinoma.

1

Hepatitis C virus (HCV) RNA detection in liver and/or peripheral blood mononuclear cells; *including HCV RNA detection in serum with nested reverse-transcription polymerase chain reaction-nucleic acid hybridization assay. HCC: Hepatocellular carcinoma.

Table 1  Prevalence and hepatitis C virus genotype distribution of occult hepatitis C virus infection

| Type                  | Country             | Prevalence¹ | Genotype | Cohort/setting               | Ref. |
|-----------------------|---------------------|-------------|----------|------------------------------|------|
| Anti-HCV negative     | Spain               | 57/100 (57%)| 1b       | Cryptogenic chronic hepatitis | [9]  |
|                       | Japan               | Not applicable | Not reported | Cryptogenic cirrhosis with HCC | [18] |
|                       | Italy               | 2/5 (40%)   | Not reported | Cryptogenic cirrhosis with HCC | [19] |
|                       | Egypt               | 4/40 (10%)  | Not reported | Cryptogenic chronic hepatitis | [20] |
|                       | Colombia            | Not applicable | 1a       | Liver retransplantation      | [21] |
|                       | Pakistan            | 25/31 (74%) | 1a, 1b, 3b | Cryptogenic chronic hepatitis | [22] |
|                       | Iran                | 7/69 (10%)  | 1a, 1b, 3a | Cryptogenic chronic hepatitis | [23] |
|                       | Italy               | 9/276 (3.3%)| 1a, 1b, 2a | General population without liver disease | [26] |
| Anti-HCV positive     | United States/Poland| 11/11 (100%)| 1a, 1b   | Asymptomatic anti-HCV carrier | [10] |
|                       | Cuba/Mexico         | 17/18 (94%) | Not reported | Asymptomatic HCV carrier and therapy response | [11] |
|                       | Spain               | 10/12 (83%) | 1b       | Asymptomatic anti-HCV carrier | [12] |
|                       | Canada              | 16/16 (100%)| 1a, 1b, 2a| Spontaneous recovery and therapy response | [13] |
|                       | United States/Poland| 15/17 (88%) | 1a, 1b, 2a, 3a | Therapy response | [14] |
|                       | Spain               | 19/20 (95%) | 1b, 2, 3 | Therapy response | [15] |
|                       | Canada              | 24/24 (100%)| 1a, 1b, 3a | Therapy response | [16] |
|                       | Egypt               | 7/62 (11%)  | Not reported | Therapy response | [20] |

1Hepatitis C virus (HCV) RNA detection in liver and/or peripheral blood mononuclear cells; *including HCV RNA detection in serum with nested reverse-transcription polymerase chain reaction-nucleic acid hybridization assay. HCC: Hepatocellular carcinoma.

HUMORAL IMMUNITY TO HCV DURING THE OCCULT INFECTION

It is unknown how HCV persists in persons who remain anti-HCV non-reactive by currently available antibody screening tests.[38] Antibodies to HCV proteins usually develop within 4-12 wk following exposure to the virus, those directed to the core and non-structural-3 region being the earliest and more frequently detected. Anti-HCV continues to be detectable throughout the duration of the infection although antibody reactivity declines over time after apparent clinical recovery of chronic hepatitis C.[39-41]. In immunocompetent individuals, the etiology of the primary occult HCV infection is most likely explained by the sporadic exposure to low infective virus doses resulting in a latent seronegative infection. Thus, anti-HCV reactivity remains undetectable due to prolonged very low antibody titres,[38], excluding persons with immunodeficiencies, immunosuppressed or suffering from a concomitant chronic infection.

Isolated reactivity to single proteins or peptides has been reported on supplemental anti-HCV assays in blood donors in samples which are either HCV RNA-positive or -negative.[42,43]. Such pattern of anti-HCV indeterminate results resembles the profile of antibody reactivity documented in some international seroconversion panels when tested on supplemental anti-HCV assays. These panels are composed of sequential samples from a single-source donor obtained throughout the antibody development which frequently show single-antigen reactivity at the initial stages of anti-HCV seroconversion. In addition, reactivity recorded as “faint band(s)” has been shown among at risk persons but seronegative by screening anti-HCV tests.[44]. At this point the criteria recommended by the supplier of the supplemental assay to validate the testing as reactive or anti-HCV-positive vs indeterminate result should be discussed. But this issue would require a thorough comparison of the HCV antigens employed by the licensed tests and the interpretation of their reactivity in particular populations, which is out of the scope of this review and deserves future investigation.

The majority of persons exposed to HCV who become infected and seroconvert to anti-HCV remain asymptomatic. Up to 80% of seropositive infections are not diagnosed because persons belong to low, or supposedly null, risk groups. Screening programs in the general population would promote awareness and prevention of HCV spread because seropositive persons may be identified and offered appropriate counselling. However, this strategy still will not identify the seronegative infections using the current screening anti-HCV tests, as evidenced by the existence of the primary occult HCV infection.

In an attempt to overcome this, an anti-HCV assay based on a well-conserved core-derived epitope has been reported recently.[45]. Briefly, wells of a microtitre plate are coated overnight with HCV-core 5-19-peptide. Wells are washed and non-specific sites are blocked with phosphate buffer saline containing Tween-20 plus heat-inactivated fetal bovine serum. Diluted serum samples are added to the HCV-core coated wells and after incubation for 1 h, wells are washed five times and incubated with horseradish peroxidase-conjugated rabbit polyclonal anti-human IgG for 1 h. After five washings wells are reacted in the dark with 2, 20-azinoisobis-[3-ethylbenzthiazoline-6-sulfonic acid]-diammonium salt. Absorbance is measured at 405 nm with a reference at 620 nm. In contrast to the NS3 sequence which shows considerable inter-genotypic heterogeneity,[46], the core sequence is largely conserved...
among genotypes 1 through 6\(^{[47]}\). Antibody to HCV core was tested in a cohort of 145 anti-HCV screening-negative patients with occult HCV infection of whom 40% were found to be anti-HCV core-positive, including 10% of individuals who were antibody non-reactive at the time of the first sample testing. Also, the anti-HCV core was detected in 99% of chronic hepatitis C patients but in none of the patients with HCV-unrelated liver disease. Thus, anti-HCV core testing allowed serological identification of up to 40% of the anti-HCV screening-negative infections on repeated testing\(^{[45]}\). The finding that a number of patients with occult infection who were initially nonreactive for anti-HCV core antibodies became positive upon subsequent testing underscores the necessity of screening serial samples as proposed by other authors\(^{[32,46]}\).

In addition, the anti-HCV core assay has been able to track HCV exposure among relatives of patients with occult HCV. Intrafamilial spread of occult HCV infection seems to occur as often as that of chronic hepatitis C\(^{[29]}\). So, anti-HCV core was detected in 23% anti-HCV-screening-negative relatives of patients with occult HCV infection. Thus, antibody testing to HCV core detected frequent exposure to and possible transmission of HCV among family members of HCV-infected patients compared with screening anti-HCV tests\(^{[50]}\). On the other hand, because patients undergoing hemodialysis are at risk of occult HCV infection\(^{[24,53]}\), testing for anti-HCV core has been evaluated in repeatedly anti-HCV screening-negative and serum HCV RNA-negative hemodialysis patients with abnormal liver enzymes. Anti-HCV core antibodies were detectable in 34% hemodialysis patients who have been exposed to HCV and who might have developed occult HCV infection (unpublished results).

Therefore, anti-HCV fails to be detected by screening tests available in some populations of at-risk patients\(^{[46]}\), including those individuals multi-exposed such as intravenous drug users or prison inmates\(^{[44,50-53]}\). The ultimate utility of the anti-HCV core-based antibody assay in those cases and other settings such as blood donors warrants further investigation.

**MAY OCCULT HCV INFECTION BE DIAGNOSED WITHOUT A LIVER BIOPSY?**

Detection of HCV RNA in the liver biopsy is the gold-standard method for the diagnosis of an occult HCV infection. However, as commented before, viral RNA is detectable in the PBMCs and in ultracentrifuged serum of patients with occult HCV\(^{[9,27]}\) and anti-core HCV tested by a non-commercial enzyme-linked immunosorbent assay (ELISA) is also found in a substantial proportion of these patients\(^{[46]}\). Therefore, in a recent report it was determined whether all cases of occult HCV infection could be diagnosed without performing a liver biopsy by combining these methods\(^{[51]}\). A total of 122 patients, who were diagnosed of an occult HCV infection by the presence of viral RNA in a liver biopsy and with available serum samples and PBMCs were included in the study. Anti-core HCV (tested with the non-commercial ELISA) was found positive in 44/122 (36%) of the patients. After ultracentrifugation of serum samples, HCV RNA was found in 70/122 (57%) of the patients, while 74/122 (61%) had viral RNA in PBMCs. When combining the detection of anti-core HCV and the detection of HCV RNA in ultracentrifuged serum and in PBMCs, 91% of the patients (111/122) were positive for at least one of these markers. So, in the light of these results, occult HCV infection may be properly diagnosed in up to 91% of the patients without the need to perform a liver biopsy by testing for anti-core HCV and for HCV RNA in ultracentrifuged serum and in PBMCs.

In summary, when occult HCV infection is suspected and a liver biopsy is not available for HCV RNA detection, the diagnosis can be made by testing, with a highly sensitive real-time PCR technique, for the presence of viral RNA in PBMCs (that identities between 60%-70% of the cases)\(^{[53]}\) or in ultracentrifuged serum (that allows identification of occult HCV in around 60% of the patients)\(^{[27,58]}\). The combination of these two approaches along with the detection of anti-core HCV improves the diagnosis of occult HCV infection in more than 90% of the cases. Nevertheless, in order to increase the percentage of patients diagnosed of occult HCV infection with non-invasive methods, more studies should be done in the future to improve the sensitivity of the above mentioned techniques.

**CHARACTERS OF OCCULT HCV INFECTION AND RESPONSE TO ANTIVIRAL TREATMENT**

Clinical characteristics of patients with occult HCV infection have been compared to those of patients with chronic hepatitis C matched with respect to age, gender and known duration of the disease\(^{[46]}\). In the study it was found that patients with occult HCV presented significantly lower values of iron, alanine aminotransferase, \(\gamma\)-glutamyl transpeptidase and \(\alpha\)-fetoprotein whereas triglycerides and cholesterol levels were significantly higher than those of patients with chronic hepatitis C. In the liver biopsies, patients with chronic hepatitis C frequently had more necroinflammation activity (96%) and fibrosis (75%) than patients with occult HCV infection (31% and 15%, respectively), but liver cirrhosis was diagnosed with a similar frequency in both groups (4.4% in occult HCV vs 7.2% in chronic hepatitis C). Although cholesterol and triglyceride levels were significantly higher in patients with occult HCV infection than in patients with chronic hepatitis C, the percentage of cases with liver steatosis did not differ significantly between these two groups, suggesting that dyslipidemic disorders did not play a predominant role in the development of steatosis in patients with occult HCV. So, occult HCV infection seems to be a milder form of the disease caused by HCV with less liver damage. However, it is important to point out that
occult HCV may lead to liver cirrhosis and therefore to the development of hepatocellular carcinoma. Regarding this issue, the presence of viral RNA in the tumour and non-tumour tissue of anti-HCV and serum HCV RNA negative patients with liver cancer has been reported. Nevertheless, the number of patients analyzed in these reports was low and further studies are needed to ascertain the role of occult HCV in causing hepatocellular carcinoma.

Taking into account that patients with occult HCV present with abnormal liver function tests and may have histological damage, a study was conducted to determine whether these patients could respond to antiviral treatment with pegylated-interferon (PEG-IFN) plus ribavirin. A total of 10 patients with occult HCV genotype 1b infection (anti-HCV and serum HCV-RNA negative but HCV RNA positive in liver) who were HCV RNA positive in PBMCs, had abnormal values of alanine aminotransferase for at least 12 mo and had necroinflammatory activity in a liver biopsy performed within one year before the study entry, were treated with standard doses of PEG-IFN plus ribavirin for 24 wk. The patients received a 24-wk treatment course instead of the recommended 48-wk course for HCV genotype 1 because they were serum HCV RNA negative. After treatment, patients were followed for 24 wk. At the end of therapy, 80% of the patients had normalized ALT values and were HCV RNA negative in PBMCs, but at the end of the post-treatment follow-up, only 3 cases remained with normal ALT values and without HCV RNA in PBMCs (complete responders). Five of the patients (2 of them with a complete response) underwent a second liver biopsy at the end of the follow-up period. Necroinflammatory activity and fibrosis scores had decreased in the post-treatment liver biopsy of 3 patients, while scores in the other 2 cases remained unchanged. Viral RNA persisted in the liver of the 5 patients but HCV RNA load was significantly lower in the post-treatment biopsy than in the basal one. Thus, treatment with PEG-IFN plus ribavirin may be beneficial in patients with occult HCV because intrahepatic HCV RNA load decreases and histological liver damage may improve but, as it has been described, eradication of occult HCV infection is not eradicated.

In conclusion, although occult HCV infection appears to be milder than “classical” chronic hepatitis C, liver fibrosis is present in up to 5% of the patients. In addition, necroinflammatory activity is detected in the liver of nearly 35% of the cases. This suggests that occult HCV infection may progress to a more serious chronic liver injury. Supporting this notion is the fact that occult HCV infection has been identified in patients with liver cirrhosis and even in hepatocellular carcinoma. Thus, the treatment of patients with occult HCV infection with PEG-IFN plus ribavirin is a reasonable option, as it is proven for chronic hepatitis C because the histological liver damage may improve with treatment. However, the infection is not completely eradicated, as described for patients with chronic hepatitis C who respond to antiviral treatment.

**IS OCCULT HCV A TRANSIENT OR A PERSISTENT INFECTION?**

In order to determine whether occult HCV infection remains over time, we have performed a study including 37 patients who were anti-HCV and serum HCV RNA negative but with viral RNA in the liver biopsy. Patients were followed for a mean time of 55 mo and serum and PBMCs samples were collected periodically for HCV RNA testing. Evidence of viral persistence in patients with occult HCV infection was found by the detection (over the observational period) of intermittent or persistent HCV RNA positivity in the ultracentrifuged serum or in PBMCs in all but one patient. These results suggest that anti-HCV negative occult HCV is a permanent infection as it has been reported in anti-HCV positive patients who resolved HCV infection. Nevertheless, in order to extend the knowledge in the natural history and the pathogenesis of occult HCV infection, a more prolonged follow-up is needed.

**GENOTYPES OF OCCULT HCV INFECTION**

In the initial studies of occult HCV infection the only HCV genotype detected was 1b. This result was predictable because HCV genotype 1b is the most prevalent genotype in Spain. However, later studies performed worldwide have reported occult HCV infection belonging to HCV genotypes 1a, 2a, 3a and 3b. So, it can be assumed that occult HCV infection is a universal phenomenon and all genotypes may be involved in this infection. This hypothesis should be proven with several studies performed in countries with different prevalence of HCV genotypes.

**ROLE OF OCCULT HCV INFECTION IN LIVER TRANSPLANTATION**

In anti-HCV positive patients with occult HCV, the reactivation of HCV infection (with reappearance of serum HCV-RNA) is well documented in special clinical situations, such as immunocompromised patients, patients on long term chemotherapy for cancer or patients receiving immunosuppressive therapy (including those who have undergone liver, kidney or bone marrow transplant). By contrast, there are no studies of the serologically silent (anti-HCV negative) occult HCV infection in these settings, except for a reported case of occult HCV infection as the cause of a liver transplantation and retransplantation. The patient was a 29-year-old man who was transplanted due to liver cirrhosis of unknown etiology. Ten months after the first liver transplant, the patient was retransplanted because of liver failure secondary to severe chronic cholestasis of unknown origin. Liver
samples of both explants were available for study. The patient has remained anti-HCV and HCV RNA negative in serum and plasma since the initial diagnosis, but viral RNA was detected in the liver tissue samples from the two explants. Furthermore, a phylogenetic analysis demonstrated that the HCV RNA isolated from the two liver samples belonged to genotype 1a. Although HCV RNA was undetectable in the PBMCs of the patient, he had an occult HCV infection and probably, the liver graft was infected by PBMCs.

This case suggests that occult HCV infection may play a role as an etiological agent of liver failure in transplanted patients. Also, this report strongly supports the need for performing studies not only in liver transplant, but also in other immunocompromised patients with unexplained elevation of liver enzymes to determine the real magnitude, clinical significance and long-term consequences of occult HCV infection.

**OCCULT HCV INFECTION IN HEALTHY POPULATION WITH NORMAL LIVER ENZYMES**

Although occult HCV infection was identified in patients with abnormal values of liver function tests, a recent work by De Marco et al. describes the existence of occult HCV infection among healthy people with normal alanine aminotransferase and normal aminotransferase values. These healthy subjects were enrolled in the frame of three different epidemiological studies: the Italy cohort series of the European Prospective Investigation into Cancer and Nutrition, the Turin Case-Control Bladder Cancer Study and the Italian project in Cervical Cancer Screening. Subjects were tested for anti-HCV and for HCV RNA in plasma and in PBMCs. All of them were anti-HCV and serum HCV RNA negative, but viral RNA was detected in the PBMCs of 9/276 (3.3%) healthy controls with normal liver enzymes. Interestingly, in the studied population, blood donors were over-sampled but the authors do not indicate if any of these blood donors had an occult HCV infection.

So, this work potentially has important implications. Thus, the frequency of occult HCV infection may be underestimated since until now this infection has been exclusively studied among patients with abnormal values of liver enzymes. In this sense, in the study of De Marco et al. the frequency of occult HCV infection in their healthy population was 3.3% vs the 2.7% prevalence of anti-HCV positivity detected in the general Italian population. Although the number of participants in the former study (276 subjects) should be increased, there is a potential risk for HCV spread from an occult HCV healthy population. Thus in blood donations, despite approaches to reduce the risk of leukocyte-related disease, such as leucodepletion, the efficacy in reducing the risk of transmitting viruses is still under debate. Furthermore, as HCV RNA may be detected after ultracentrifugation of serum samples in more than 50% of patients with occult HCV infection, and this test was not performed in the Italian study, it may be possible that healthy blood donors have HCV RNA in serum undetectable by conventional PCR assays. If this is the case, blood donors with occult HCV infection may potentially transmit this occult infection as it is undetectable by the current applied screening tests for HCV in blood banks. However, more studies should be performed in healthy subjects with normal liver enzymes and especially among blood donors to definitively establish the possible magnitude of this infection.

**CONCLUSION**

Occult HCV infection has been found in two different settings: in anti-HCV positive, serum HCV RNA negative patients with normal levels of liver enzymes and in anti-HCV negative, serum HCV RNA negative patients with abnormal liver function tests of unknown etiology. Occult HCV is distributed worldwide and all viral genotypes may be involved. Although seronegative occult HCV infection seems to be less aggressive than classical chronic hepatitis C, it has been detected in patients with liver cirrhosis and even in hepatocellular carcinoma. Occult HCV infection has been described also in a healthy population with no evidence of liver disease, indicating that this infection may be present in a wide spectrum of clinical situations. Further studies on the natural history and the clinical significance of occult HCV infection are needed to determine its global prevalence, infectivity, implication in causing extrahepatic diseases and its long-term complications in special circumstances such as immunocompromised patients.

**REFERENCES**

1. Bartenschlager R, Lohmann V. Replication of hepatitis C virus. J Gen Virol 2000; 81: 1631-1648
2. Poenisch M, Bartenschlager R. New insights into structure and replication of the hepatitis C virus and clinical implications. Semin Liver Dis 2010; 30: 333-347
3. Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 1995; 15: 41-63
4. Bostan N, Mahmood T. An overview about hepatitis C: a devastating virus. Crit Rev Microbiol 2010; 36: 91-133
5. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-567
6. Alberti A, Chemello L, Benvegnü L. Natural history of hepatitis C virus. J Hepatol 1999; 31 Suppl 1: 17-24
7. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374
8. Pawlotsky JM, Lonjon I, Hezode C, Raynard B, Darthu F, Remire J, Soussy CJ, Dhumeaux D. What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories? Hepatology 1998; 27: 1700-1702
9. Castillo I, Pardo M, Bartolomé J, Ortiz-Movilla N, Rodríguez-Iturgo E, de Lucas S, Salas C, Jiménez-Heffernan JA, Pérez-Mota A, Graus J, López-Alcorocho JM, Carreño V, Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown. J Infect Dis 2004; 189: 7-14
10. Radkowski M, Horban A, Gallegos-Orozco JF, Pawelczyk A,
Jablonska J, Wilkinson J, Adair D, Laskus T. Evidence for viral persistence in patients who test positive for anti-hepatitis C virus antibodies and have normal alanine aminotransferase levels. *J Infect Dis* 2005; 191: 1730-1733.

21 Falcón V, Acosta-Rivero N, Shihayama M, Luna-Munoz J, Miranda-Sanchez M, de la Rosa MC, Menéndez I, Gra B, Dueñas-Carrera S, García W, Vilar E, Silva J, López D, González-Bravo M, Fernández-Ortega C, Casillas D, Morales J, Kouri J, Tsutsumi V. Evidences of hepatitis C virus replication in hepatocytes and peripheral blood mononuclear cells from patients negative for viral RNA in serum. *Am J Infect Dis* 2005; 1: 34-42.

22 Carreño V, Pardo M, López-Alcorocho JM, Rodríguez-Inígo E, Bartolomé J, Castillo I. Detection of hepatitis C virus (HCV) RNA in the liver of healthy, anti-HCV antibody-positive, serum HCV RNA-negative patients with normal alanine aminotransferase levels. *J Infect Dis* 2006; 194: 53-60.

23 Pham TN, MacParland SA, Mulrooney PM, Cooksley H, Naoumov NV, Michalik TL. Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. *J Virol* 2004; 78: 5867-5874.

24 Radkowski M, Gallegos-Orozco JF, Jablonska J, Colby TV, Walewska-Zielecka B, Kubicka J, Wilkinson J, Adair D, Rakela J, Laskus T. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. *Hepatology* 2005; 41: 106-114.

25 Castillo I, Rodríguez-Inígo E, López-Alcorocho JM, Pardo M, Bartolomé J, Carreño V. Hepatitis C virus replicates in the liver of patients with a sustained response to antiviral treatment. *Clin Infect Dis* 2006; 43: 1277-1283.

26 Pham TN, Coffin CS, Churchill ND, Urbanski SJ, Lee SS, Michalik TL. Hepatitis C virus persistence after sustained virological response to antiviral therapy in patients with or without past exposure to hepatitis B virus. *J Viral Hepat* 2012; 19: 103-111.

27 Castillo I, Rodríguez-Inígo E, Bartolomé J, de Lucas S, Ortiz-Movilla N, López-Alcorocho JM, Pardo M, Carreño V. Hepatitis C virus replicates in peripheral blood mononuclear cells of patients with occult hepatitis C virus infection. *Gut* 2005; 54: 682-685.

28 Esaki T, Suzuki N, Yokoyama K, Iwata K, Irie M, Anan A, Nakane H, Yoshikane M, Nishizawa S, Ueda S, Sohda T, Watanabe H, Sakisaoka S. Hepatocellular carcinoma in a patient with liver cirrhosis associated with negative serum HCV tests but positive liver tissue HCV RNA. *Intern Med* 2004; 43: 279-282.

29 Comar M, Dal Molin G, D’Agraro P, Croce SL, Tiribelli C, Campello CBV, HCV, and TTV detection by in situ polymerase chain reaction could reveal occult hepatitis in hepatocellular carcinoma: comparison with blood markers. *J Clin Pathol* 2006; 59: 526-529.

30 Zaghoul H, El-Sherbiny W. Detection of occult hepatitis C and hepatitis B virus infections from peripheral blood mononuclear cells. *Immunol Invest* 2010; 39: 284-291.

31 Cortés-Mancera FM, Restrepo JC, Osorio G, Hoyos S, Correa G, Navas MC. Occult hepatitis C virus infection in a retransplanted patients with liver failure of unknown etiology. *Rev Col Gastroenterol* 2011; 72: 70-80.

32 Idrees M, Lal A, Malik FA, Hussain A, Rehman I, Akbar H, Butt S, Ali M, Ali L, Malik FA. Occult hepatitis C virus infection and associated predictive factors: the Pakistan experience. *Infect Genet Evol* 2011; 11: 442-445.

33 Bokharaei-Salim F, Keyhani H, Monavari SH, Alavian SM, Madjid Z, Toosi MN, Alizadeh AH. Occult hepatitis C virus infection in Iranian patients with cryptogenic liver disease. *J Med Virol* 2011; 83: 989-995.

34 Barril G, Castillo I, Arenas MD, Espinosa M, García-Valdecasas J, García-Fernández N, González-Parra E, Alcazar JM, Sánchez C, Diez-Baylón JC, Martínez P, Bartolomé J, Carreño V. Occult hepatitis C virus infection among hemodialysis patients. *J Am Soc Nephrol* 2008; 19: 2288-2292.

35 Castillo I, Bartolomé J, Quiroga JA, Barril G, Carreño V. Hepatitis C virus infection in the family setting of patients with occult hepatitis C. *J Med Virol* 2009; 81: 1198-1203.

36 De Marco L, Gillo-Toia A, Fanfani F, Romao K, Gizio V, Palli D, Panico S, Tumino R, Vinesi P, Merletti F, Richardt L, Sarc-e-dote C. Occult HCV infection: an unexpected finding in a population unselected for hepatic disease. *PLoS One* 2009; 4: e8128.

37 Bartolomé J, López-Alcorocho JM, Castillo I, Rodríguez-Inígo E, Goico E, Quiroga JA, Palacios R, Carreño V. Ultra-centrifugation of serum samples allows detection of hepatitis C virus RNA in patients with occult hepatitis C. *J Viral Hepat* 2007; 14: 7710-7715.

38 Nielsens SU, Bassendine MF, Burt AD, Martin C, Pumeechookchai W, Toms GL. Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients. *J Viral* 2006; 80: 2418-2428.

39 Quiroga JA, Llorente S, Castillo I, Rodríguez-Inígo E, Pardo M, Carreño V. Cellular immune responses associated with occult hepatitis C virus infection. *J Viral Hepat* 2006; 13: 10972-10979.

40 Carreño V, Bartolomé J, Castillo I, Quiroga JA. Occult hepatitis B virus and hepatitis C virus infections. *Rev Med Virol* 2011; 18: 139-157.

41 Rico MA, Ruiz S, Subirà D, Barril G, Cigarrán S, Castañón S, Quiroga JA, Selgas R, Carreño V. Virus-specific effector CD4+ T-cell responses in hemodialysis patients with hepatitis C virus infection. *J Med Virol* 2004; 72: 66-74.

42 Pham TN, Coffin CS, Michalik TL. Occult hepatitis C virus infection: what does it mean? *Liver Int* 2010; 30: 502-511.

43 Pham TN, Mercer SE, Michalik TL. Chronic hepatitis C and persistent occult hepatitis C virus infection are characterized by distinct immune cell cytokine expression profiles. *J Viral Hepat* 2009; 16: 547-556.

44 Quiroga JA, Llorente S, Castillo I, Rodríguez-Inígo E, López-Alcorocho JM, Pardo M, Carreño V. Virus-specific T-cell responses associated with hepatitis C virus (HCV) persistence in the liver after apparent recovery from HCV infection. *J Med Virol* 2006; 78: 1190-1197.

45 Barril G, Quiroga JA, Espinosa M, Arenas D, García-Valdecasas J, González-Parra E, García-Fernández N, Alcazar JN, Sánchez-González MC, Martínez-Rubio P, Llorente S, Castillo I, Bartolomé J, Carreño V. Hepatitis C virus (HCV)-specific T-cell responses are often detectable among hemodialysis patients at risk of occult HCV infection. *Clinical Kidney Journal* 2009; 2 (suppl 2): 1353.

46 Quiroga JA, Llorente S, Castillo I, Bartolomé J, Barril G, Carreño V. Tracking intrafamilial spread of serologically silent occult HCV infection through humoral and cellular HCV-specific responses. *J Hepatol* 2009; 50: S149.

47 Veerapu NS, Raghruman S, Liang TJ, Keller T, Rehermann B. Sporadic reappearance of minute amounts of hepatitis C virus RNA after successful therapy stimulates cellular immune responses. *Gastroenterology* 2011; 140: 676-685.e1.

48 Quiroga JA, Castillo I, Pardo M, Rodríguez-Inígo E, Carreño V. Combined hepatitis C virus (HCV) antigen-antibody detection assay does not improve diagnosis for seronegative individuals with occult HCV infection. *J Clin Microbiol* 2006; 44: 4559-4560.

49 Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebertrau A, Miller JL, Manns MP, Rehermann B. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. *Nat Med* 2000; 6: 578-582.

50 Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Kuzuya T, Honda T, Hayashi K, Nakano I, Katano Y, Goto H. Changes in hepatitis C virus (HCV) antibody status in patients with chronic hepatitis C after eradication of HCV infection by interferon therapy. *Clin Infect Dis*
Carreño V et al. Occult HCV infection

2005; 40: e49-e54

Unemura T, Wang RY, Schechterl C, Shih JW, Kiyosawa K, Alter HJ. Quantitative analysis of anti-hepatitis C virus antibody-secreting B cells in patients with chronic hepatitis C. Hepatology 2006; 43: 91-99

Semmo N, Barnes E, Taylor C, Kurtz J, Harcourt G, Smith N, Klenerman P. T-cell responses and previous exposure to hepatitis C virus in indeterminate blood donors. Lancet 2005; 365: 327-329

Echevarría JM, Avellón A, Jonas G, Hausmann M, Voelck A, Kapprell HP. Sensitivity of a modified version of the AR-CHITECT Anti-HCV test in detecting samples with immuno-blotted-confirmed, low-level antibody to hepatitis C virus. J Clin Virol 2006; 35: 368-372

Post JJ, Pan Y, Freeman AJ, Harvey CE, White PA, Palladini P, Haber PS, Marinos G, Levy MH, Kaldor JM, Dolan KA, French RA, Lloyd AR, Rawlinson WD. Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort. J Infect Dis 2004; 189: 1846-1855

Quiroga JA, Castillo I, Llorente S, Bartolomé J, Barril G, Carreño V. Identification of serologically silent occult hepatitis C virus infection by detecting immunoglobulin G antibody to a dominant HCV core peptide epitope. J Hepatol 2009; 50: 256-263

Lodrini S, Bagaglio S, Canducci F, De Mitri MS, Andreone P, Loggi E, Lazzarin A, Clementi M, Morsica G. Sequence analysis of NS3 protease gene in clinical strains of hepatitis C virus. J Biol Regul Homeost Agents 2003; 17: 198-204

Bukh J, Purcell RH, Miller RH. Sequence analysis of the core gene of 14 hepatitis C virus genotypes. Proc Natl Acad Sci USA 1994; 91: 8239-8243

Pham TN, Mulrooney-Cousins PM, Mercer SE, MacFarland SA, Inglot M, Zaleswka M, Simon K, Michalak TL. Antagonistic expression of hepatitis C virus and alpha interferon with a sustained virological response may predict reactivation of hepatitis C virus infection. J Hepatol 2008; 18-22

Zeremski M, Shu MA, Brown Q, Wu Y, Des Jarlais DC, Busch MP, Talal AH, Edlin BR. Hepatitis C virus-specific T-cell responses in seronegative injection drug users. J Viral Hepat 2009; 16: 10-20

Castillo I, Bartolomé J, Quiroga JA, Barril G, Carreño V. Diagnosis of occult hepatitis C without the need for a liver biopsy. J Med Virol 2010; 82: 1554-1559

Pardo M, López-Alcorocho JM, Rodríguez-Iñigo E, Castillo I, Carreño V. Comparative study between occult hepatitis C virus infection and chronic hepatitis C. J Viral Hepat 2007; 14: 36-40

Pardo M, López-Alcorocho JM, Castillo I, Rodríguez-Iñigo E, Perez-Mota A, Carreño V. Effect of anti-viral therapy for occult hepatitis C virus infection. Aliment Pharmacol Ther 2006; 23: 1153-1159

Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Idoe G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHT). Lancet 1998; 352: 1426-1432

Manus MP, McHutchison JG, Gordon SC, Rustig VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965

EASL International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, Consensus Statement. European Association for the Study of the Liver. J Hepatol 1999; 30: 956-961

Alberti A. Impact of a sustained virological response on the long-term outcome of hepatitis C. Liver Int 2011; 31 Suppl 1: 18-22

Castillo I, Bartolomé J, Quiroga JA, Barril G, Carreño V. Long-term virological follow up of patients with occult hepatitis C virus infection. Liver Int 2011; 31: 1519-1524

Castillo I, Bartolomé J, Quiroga JA, Barril G, Carreño V. Presence of HCV-RNA after ultracentrifugation of serum samples during the follow-up of chronic hepatitis C patients with a sustained virological response may predict reactivation of hepatitis C virus infection. Aliment Pharmacol Ther 2009; 30: 477-486

Basarás M, Lombera N, de las Heras B, López C, Arrese E, Cisterna R. Distribution of HCV genotypes in patients infected by different sources. Res Virol 1997; 148: 367-373

Ramos B, Núñez M, Toro C, Sheldon J, Garcia-Samaniego J, Rios P, Soriano V. Changes in the distribution of hepatitis C virus (HCV) genotypes over time in Spain according to HIV serostatus: implications for HCV therapy in HCV/HIV-coinfected patients. J Infect 2007; 54: 173-179

Vento S, Cainelli F, Longhi MS. Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. Lancet Oncol 2002; 3: 333-340

Melisko ME, Fox R, Vennik A. Reactivation of hepatitis C virus after chemotherapy for colon cancer. Clin Oncol (R Coll Radiol) 2004; 16: 204-205

Zekri AR, Mohamed WS, Samra MA, Sherif GM, El-Shehaby AM, El-Sayed MH. Risk factors for cytomegalovirus, hepatitis B and C virus reactivation after bone marrow transplantation. Transpl Immunol 2004; 13: 305-311

Melson S, Galarraga MC, Villar M, Laures A, Boga JA, de Oña M, Gomez E. Hepatitis C virus reactivation in anti-hepatitic C virus-positive renal transplant recipients. Transplant Proc 2005; 37: 2083-2085

Lee WM, Polson JE, Carney DS, Sahin B, Gale M. Reemergence of hepatitis C virus after 8.5 years in a patient with hypogammaglobulinemia: evidence for an occult viral reservoir. J Infect Dis 2005; 192: 1088-1092

Lin A, Thadreddy A, Goldstein MJ, Lake-Bakaar G. Immune suppression leading to hepatitis C virus re-emergence after sustained virological response. J Med Virol 2008; 80: 1720-1722

Kopko PM, Holland PV. Universal leukocyte reduction. Curr Opin Hematol 2000; 7: 397-401